NoV GI.1/GII.4 Bivalent VLP Vaccine

BIOLOGICAL3 trials

Sponsors

Takeda

Conditions

GastroenteritisHealthy ParticipantsHealthy VolunteersNorovirus

Phase 1

Bivalent Norovirus Vaccine Study

CompletedNCT01168401

TakedaGastroenteritis

Start: 2010-09-03End: 2013-01-09Updated: 2018-11-23

Phase 2

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

CompletedNCT02475278

TakedaHealthy Participants, Norovirus

Start: 2015-02-26End: 2015-09-09Updated: 2018-02-22

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

CompletedNCT02669121

TakedaHealthy Volunteers

Start: 2016-06-14End: 2018-06-16Updated: 2021-06-10

Related Papers

Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen–Blocking Antibody Levels

The Journal of Infectious Diseases2024-06-112 citations

Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial

UNC Libraries2020-11-07

Comparison of Microneutralization and Histo-Blood Group Antigen–Blocking Assays for Functional Norovirus Antibody Detection

The Journal of Infectious Diseases2019-10-0957 citations

B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine

Clinical and Vaccine Immunology2017-03-0222 citations

Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial

PLoS Medicine2015-03-24141 citations

A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate—Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults

The Journal of Infectious Diseases2014-06-20141 citations